Appistry, a leading provider of solutions that simplify the analysis of next-generation sequencing (NGS) data, announced today integrated solutions that automate NGS workflows to help clinical labs reduce the barrier of entry and costs associated with NGS based testing.
Expanding on Appistry’s current NGS analysis offering, the end-to-end solution features new interpretation capabilities within GenomeNavigator™ and leverages the genomics workflow platform from GenomePilot™ to automate the entire process from reads to report.
“One of the biggest challenges for a lab running NGS based tests or one looking to start, is the barrier of entry and costs associated with analyzing the sequencing data,” said Kevin Haar CEO of Appistry. “We have found lab directors require more than the disparate bioinformatics platforms and interpretation tools available on the market today. Instead of addressing pieces of the workflow, our goal is to enable the automation of the entire workflow, providing an easier path for labs to establish or expand their NGS testing capabilities and improve productivity and costs.”
Appistry’s GenomePilot will automate the execution of NGS tests from the lab’s sequencer through the identification, qualification and prioritization of variants. Each case is presented in GenomeNavigator for first review, where a molecular pathologist can either approve the prioritized variants for clinical reporting, or in more complex cases, conduct further investigation using GenomeNavigator’s interactive interpretation environment.
Appistry will debut their end-to-end solution during the week of September 19th at two industry conferences.
GenomePilot™ enables labs to automate the process of identifying reportable variants with an integrated, scalable and compliant data analysis platform. With a focus on making the analysis of NGS data more approachable and accessible, GenomePilot integrates analytics, compliance and infrastructure into a single solution, enabling end-to-end lab analytics workflow automation.
GenomeNavigator enhances and accelerates the process for interpreting and reporting clinically relevant variants. Through an intuitive dashboard, clinicians can quickly review and approve prioritized variants or conduct further investigation using the interactive analysis environment, enabling information driven interpretation.
Appistry is a scientific software company that bridges the gap between genomics data and health outcomes by making next-generation sequencing data analysis more approachable and actionable to improve clinical decisions. With roots in high-performance computing, big data, and life sciences we bring a unique level of expertise to helping our customers solve complex problems and transform data into actionable information.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919005342/en/Business Wire
Last updated on: 19/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.